MEDLATEC OncoSure Plus Hereditary Cancer Risk Test

OncoSure Plus is a comprehensive hereditary cancer genetic risk assessment offered by MEDLATEC, designed to identify inherited genetic variants associated with susceptibility to multiple cancer conditions.

The test analyses 145 genes associated with 30 hereditary cancer conditions, providing a broader genetic assessment than standard OncoSure and smaller, cancer-specific genetic panels.

Unlike blood-based tests that screen for cancer-associated signals, OncoSure Plus evaluates inherited genetic susceptibility. It does not determine whether cancer is currently present.

What Does OncoSure Plus Assess?

• Inherited Cancer Susceptibility

OncoSure Plus examines genetic variants associated with hereditary cancer predisposition.

• A Broad Range of Hereditary Cancer Conditions

The panel covers 30 hereditary cancer conditions through the analysis of 145 genes.

• Genetic Information Relevant to Family Health

Certain inherited variants may have implications for biological relatives. Genetic counselling can help patients understand whether family members should consider further assessment.

The exact genes, conditions and testing limitations should be reviewed using MEDLATEC's current panel documentation.

Key Benefits of OncoSure Plus

• Extensive 145-Gene Analysis

OncoSure Plus examines 145 genes associated with hereditary cancer susceptibility, offering a broader assessment than smaller genetic testing panels.

• Assessment Across 30 Hereditary Cancer Conditions

The test covers 30 hereditary cancer conditions, supporting a more extensive evaluation of inherited cancer risk.

• Supports Personalised Preventive Healthcare

Genetic findings may help healthcare professionals discuss appropriate screening strategies, risk management and additional medical evaluation.

• Valuable for Complex Family Cancer Histories

A broader panel may be considered when personal or family history suggests the possibility of more than one hereditary cancer syndrome.

• Provides Information for Family Risk Assessment

Some clinically significant inherited variants may also be relevant to biological relatives. Genetic counselling can help determine whether family testing is appropriate.

• Generally a One-Time Genetic Assessment

Inherited genetic variants are generally stable throughout life, so routine annual repetition of the same germline genetic test is usually unnecessary. Additional testing or reinterpretation may be appropriate as genetic knowledge and clinical circumstances change.

Who May Consider OncoSure Plus?

OncoSure Plus may be considered by individuals who:

• Have multiple biological relatives diagnosed with different types of cancer.

• Have a family history of cancer diagnosed at relatively young ages.

• Have a personal or family history suggestive of hereditary cancer syndromes.

• Have previously undergone a limited genetic panel and require further evaluation.

• Have been advised by a qualified healthcare professional to consider expanded genetic testing.

• Want to discuss comprehensive hereditary cancer risk assessment as part of preventive healthcare planning.

A broader genetic panel is not necessarily the most appropriate option for every individual. Test selection should be guided by personal history, family history and genetic counselling.

Testing Process

1. Pre-Test Consultation: Review medical history, family cancer history, testing suitability and potential implications of genetic results.

2. Sample Collection: A biological sample is collected according to MEDLATEC's laboratory requirements.

3. Genetic Analysis: The laboratory analyses the selected 145-gene panel.

4. Results: Results are generally expected in approximately 15 working days, subject to laboratory confirmation.

5. Genetic Counselling and Follow-Up: A qualified healthcare professional explains the findings and discusses appropriate next steps.

Understanding Your Results

• Pathogenic or Likely Pathogenic Variant

A clinically significant inherited genetic variant may indicate increased susceptibility to certain cancers. It does not mean cancer is currently present or will definitely develop.

• No Reportable Pathogenic Variant Identified

A negative result does not eliminate hereditary or non-hereditary cancer risk. Other genetic factors, family history and environmental influences may still contribute to overall risk.

• Variant of Uncertain Significance (VUS)

Some genetic variants cannot currently be classified as harmful or harmless. Such findings generally should not independently determine medical management.

Key Data

• Test Name: OncoSure Plus

• Test Category: Comprehensive Hereditary Cancer Genetic Risk Assessment

• Genetic Panel: 145 Genes

• Conditions Assessed: 30 Hereditary Cancer Conditions

• Purpose: Assessment of Inherited Cancer Susceptibility

• Expected Result Time: Approximately 15 Working Days

Your Healthcare Journey in Vietnam with MediHub

MediHub supports international patients travelling to Vietnam for healthcare services, including genetic testing and preventive healthcare planning.

Our support services may include:

• Healthcare service and genetic testing consultation

• Appointment scheduling with MEDLATEC

• Pre-arrival guidance and preparation

• Visa and travel assistance where required

• Airport transfers and local transportation

• Accommodation arrangements

• Medical interpreter coordination

• Assistance during medical appointments

• Medical results and follow-up coordination

• Travel and tourism arrangements during your stay

Plan Your Genetic Testing Journey in Vietnam

Interested in understanding your hereditary cancer risk?

Contact MediHub for personalised assistance in planning your genetic testing journey in Vietnam. Our team can help coordinate your OncoSure Plus appointment with MEDLATEC, provide pre-arrival guidance and assist with travel and follow-up arrangements.

Important Medical Information

OncoSure Plus is a hereditary genetic risk assessment, not a test for diagnosing cancer or detecting an existing tumour.

An increased genetic risk does not mean cancer will necessarily develop, and a negative result does not eliminate cancer risk.

Genetic testing results should be interpreted by appropriately qualified healthcare professionals, ideally with access to genetic counselling. Recommended cancer screening and clinical assessment may still be necessary regardless of the genetic test result.